Highlights Newsletter 1

This newsletter presents you the following key sessions:

• Update of STAMPEDE Trial: Adding Abiraterone to Standard Treatment Improves Survival in Advanced Prostate Cancer. Video-interview with Nicholas James, PhD, Professor of Clinical Oncology, Queen Elizabeth Hospital, Birmingham, UK

• Adjuvant capecitabine prolongs the survival of biliary tract cancer with more than 1 year

• SCORAD III study reveals: one radiation treatment is sufficient to relieve spinal cord compression symptoms

• Gefitinib enhances DFS with 10 months compared to platinum-based chemotherapy in EGFR-mutation positive, intermediate-stage non-small cell lung cancer

• Routine molecular screening of advanced refractory cancer patients: feasible, but beneficial only for some